Newsroom

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth today announced the official launch of the Haynes Heart & Vascular Institute, recognizing the transformational generosity and enduring legacy of the late Bill Haynes and Reta Haynes, whose vision and philanthropy helped shape one of the North Bay's premier cardiovascular programs. The naming of the Institute celebrates the Haynes family's longstanding commitment to advancing heart care and reflects MarinHealth's continued investment in innovat...

WASHINGTON--(BUSINESS WIRE)--Xylem Inc. (NYSE: XYL), ein weltweit führendes Unternehmen für Wasserlösungen, gab heute die Ernennung von zwei Führungskräften zum 1. Juli bekannt, die beide President und Chief Executive Officer Matthew Pine unterstehen. Meredith Emmerich wurde in das Amt des EVP und President, Measurement und Control Solutions, berufen. Zuletzt war sie als EVP und President, Applied Water, bei Xylem tätig. Emmerich wechselte 2024 zu Xylem von der Carrier Global Corporation (NYSE:...

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions (NYSE: ULS), a global leader in applied safety science, issued a public notice regarding Zinshine Water Based Fire Extinguishers, which bear unauthorized UL Certification Marks for the United States and Canada and may pose safety risks. The affected products have not been evaluated by UL Solutions against the appropriate safety standards, and it is unknown whether they meet any safety requirements. UL Solutions recommends that these fire extinguis...

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today responded to the European Commission’s June 30 press release announcing an investigation involving the Company based on a complaint made by an Align competitor. Align Technology is comm...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了第三期MANGROVE研究(BGB-3111-306; NCT04002297)的正面初步主要結果。該研究評估了基礎性BTK抑制劑BRUKINSA® (zanubrutinib)聯合rituximab對比bendamustine聯合rituximab (BR)在既往未經治療的套細胞淋巴瘤(MCL)成人病患中的療效。MANGROVE是第一個在此類病患中評估以BTK抑制劑為基礎的無化療方案對比標準化療免疫療法的第三期全球性隨機試驗。這項關鍵的第三期試驗建立在BRUKINSA治療MCL的已有臨床證據基礎之上。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示： 「對於新診斷的MCL病患，化療目前是默認選擇。MANGROVE首次證明，BRUKINSA聯合rituximab這一無化療方案，能夠帶來前所未見的無惡化存活期改善，可望在全球重新定義治療...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa global de oncologia, anunciou hoje resultados preliminares positivos do estudo de Fase 3 MANGROVE (BGB-3111-306; NCT04002297), que avalia o inibidor de BTK de referência BRUKINSA®(zanubrutinibe) associado ao rituximabe em comparação com bendamustina associada ao rituximabe (BR) em pacientes adultos com linfoma de células do manto (LCM) não tratado anteriormente. O MANGROVE é o pr...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd’hui les les résultats préliminaires positifs de l’étude de phase III MANGROVE (BGB-3111-306 ; NCT04002297) évaluant BRUKINSA® (zanubrutinib), un inhibiteur de BTK servant de traitement de base, associé au rituximab par rapport à la bendamustine associée au rituximab (BR) chez des patients adultes atteints d’un lymphome à c...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa oncológica internacional, anunció hoy resultados preliminares positivos del estudio de fase 3 MANGROVE (BGB-3111-306; NCT04002297 ) que evalúa el inhibidor de la tirosina quinasa de Bruton como tratamiento base, BRUKINSA® (zanubrutinib), en combinación con rituximab, frente al tratamiento de bendamustina y rituximab en pacientes adultos con linfoma de células del manto (LCM) que no hab...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica globale, oggi ha annunciato i risultati iniziali positivi dallo studio di fase 3 MANGROVE (BGB-3111-306; NCT04002297) volto a valutare l'inibitore fondamentale della tirosin-chinasi di Bruton (BTK) BRUKINSA® (zanubrutinib) in combinazione con rituximab rispetto a bendamustine più rituximab (BR) nei pazienti adulti affetti da linfoma delle cellule mantellari (MCL) non preceden...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een bedrijf dat wereldwijd actief is op het gebied van oncologie, heeft vandaag positieve voorlopige resultaten bekendgemaakt van het fase 3-onderzoek MANGROVE (BGB-3111-306; NCT04002297. In de studie werd de toonaangevende BTK-remmer BRUKINSA® (zanubrutinib) in combinatie met rituximab vergeleken met bendamustine in combinatie met rituximab (BR) bij volwassen patiënten met niet eerder behandeld m...